Literature DB >> 19417625

Cytokeratin-positive cells in the bone marrow of breast cancer patients and noncancer donors.

David N Krag1, Roberto Kusminsky, Edward Manna, Donald Weaver, Seth P Harlow, Michael Covelli, Mary A Stanley, Laurence McCahill, Frank Ittleman, Bruce Leavitt, Martin Krag, Patricia Amarante.   

Abstract

Detection of disseminated tumor cells in the bone marrow may provide important prognostic information in breast cancer patients. With few exceptions the number of stained cells scored as cancer is very low; there may be only 1 cell per slide. This makes definitive interpretation of cancer in marrow challenging. False-positive staining of marrow cells with cytokeratin (CK) antibody is relatively common and makes interpretation more difficult. In this report we focus on false-positive staining of marrow specimens from breast cancer patients and noncancer controls and demonstrate that the frequency of false-positive events is common. Bone marrow was collected from 23 cancer-free donors and 60 breast cancer patients. Samples were processed by Ficoll density gradient centrifugation and slides were prepared for immunocytochemical staining with CK and irrelevant (IR) antibody. Slides were evaluated manually and positive cells were categorized as tumor cells, hematopoetic cells, or questionable cells. False-positive staining events were commonly observed in noncancer cases stained with CK or IR antibodies and in breast cancer cases stained with IR antibody. There was little difference in the number of breast cancer marrow specimens scored as tumor cells regardless of whether the antibody used was CK or IR. It is important to devise improved criteria and methods for accurate detection and interpretation of disseminated tumor cells in the marrow of breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19417625      PMCID: PMC2836413          DOI: 10.1097/PAI.0b013e31819f4d6b

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  20 in total

1.  The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence.

Authors:  W Janni; F Hepp; D Rjosk; C Kentenich; B Strobl; C Schindlbeck; P Hantschmann; H Sommer; K Pantel; S Braun
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

2.  Detection of isolated tumor cells in bone marrow in early-stage breast carcinoma patients: comparison with preoperative clinical parameters and primary tumor characteristics.

Authors:  B Naume; E Borgen; G Kvalheim; R Kåresen; H Qvist; T Sauer; T Kumar; J M Nesland
Journal:  Clin Cancer Res       Date:  2001-12       Impact factor: 12.531

3.  Characterization of two Fc receptors for mouse immunoglobulins on human monocytes and cell lines.

Authors:  J G Van de Winkel; W J Tax; M C Van Bruggen; C E Van Roozendaal; H W Willems; A Vlug; P J Capel; R A Koene
Journal:  Scand J Immunol       Date:  1987-12       Impact factor: 3.487

4.  Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up.

Authors:  G Gebauer; T Fehm; E Merkle; E P Beck; N Lang; W Jäger
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

5.  Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.

Authors:  B Gerber; A Krause; H Müller; D Richter; T Reimer; J Makovitzky; C Herrnring; U Jeschke; G Kundt; K Friese
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

6.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer.

Authors:  G Wiedswang; E Borgen; R Kåresen; G Kvalheim; J M Nesland; H Qvist; E Schlichting; T Sauer; J Janbu; T Harbitz; B Naume
Journal:  J Clin Oncol       Date:  2003-09-15       Impact factor: 44.544

7.  Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcome.

Authors:  Gro Wiedswang; Elin Borgen; Rolf Kåresen; Hanne Qvist; Jan Janbu; Gunnar Kvalheim; Jahn M Nesland; Bjørn Naume
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

8.  Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody-induced T cell proliferation.

Authors:  W J Tax; F F Hermes; R W Willems; P J Capel; R A Koene
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

9.  The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells.

Authors:  Bjørn Naume; Gro Wiedswang; Elin Borgen; Gunnar Kvalheim; Rolf Kåresen; Hanne Qvist; Jan Janbu; Torstein Harbitz; Jahn M Nesland
Journal:  Clin Cancer Res       Date:  2004-05-01       Impact factor: 12.531

10.  Detection of isolated tumor cells in BM from breast-cancer patients: significance of anterior and posterior iliac crest aspirations and the number of mononuclear cells analyzed.

Authors:  G Wiedswang; E Borgen; R Karesen; B Naume
Journal:  Cytotherapy       Date:  2003       Impact factor: 5.414

View more
  2 in total

1.  Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic Patients.

Authors:  Xi Zhang; Simone Hofmann; Brigitte Rack; Nadia Harbeck; Udo Jeschke; Sophie Sixou
Journal:  Int J Mol Sci       Date:  2017-06-20       Impact factor: 5.923

2.  Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study.

Authors:  Anna-Karin Falck; Pär-Ola Bendahl; Christian Ingvar; Jorma Isola; Per-Ebbe Jönsson; Pia Lindblom; Kristina Lövgren; Karin Rennstam; Mårten Fernö; Lisa Rydén
Journal:  BMC Cancer       Date:  2012-09-11       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.